Jaguar Health (JAGX) officer receives stock and option grants

Rhea-AI Filing Summary

Jaguar Health, Inc. reported an equity compensation award to executive Steven R. King, who serves as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary. On December 11, 2025, he was granted 11,740 shares of common stock, bringing his directly held common stock to 11,885 shares. These shares reflect restricted stock units granted under the company’s 2014 Stock Incentive Plan and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date.

On the same date, King also received a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests in equal monthly installments over 12 months from the grant date, contingent on his continued employment. Both the restricted stock units and options were approved by the board of directors as part of the company’s stock incentive program, and were reported as directly owned.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider King Steven R.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,740	$0.00	--
Grant/Award	Common Stock	11,740	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 11,740 shares (Direct); Common Stock — 11,885 shares (Direct)

Footnotes (1)

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

King Steven R.

(Last) (First) (Middle)

C/O JAGUAR HEALTH, INC.

200 PINE ST., STE 400

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/11/2025(2)(3)		A		11,740	A	$0	11,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$1.44	12/11/2025(2)		A		11,740		(4)	12/11/2035	Common Stock	11,740	$0	11,740	D

Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.

4. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Remarks:

Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary

	/s/ Steven R. King	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jaguar Health (JAGX) report for Steven R. King?

Jaguar Health reported that executive Steven R. King received an equity grant consisting of 11,740 shares of common stock (in the form of restricted stock units) and a stock option for 11,740 shares with a $1.44 exercise price, all granted on December 11, 2025.

How many Jaguar Health (JAGX) shares does Steven R. King hold after this Form 4 transaction?

Following the reported grant, Steven R. King is shown as beneficially owning 11,885 shares of common stock directly, according to the Form 4.

What are the vesting terms of Steven R. King’s restricted stock units at Jaguar Health (JAGX)?

Each restricted stock unit represents a right to receive one share of Jaguar Health voting common stock. The 11,740 restricted stock units vest on December 11, 2026, and vested shares will be delivered to King on the vesting date specified in the grant notice.

What are the key terms of Steven R. King’s stock option grant from Jaguar Health (JAGX)?

The stock option covers 11,740 shares of common stock at an exercise price of $1.44 per share. It becomes exercisable in monthly installments over 12 months from the December 11, 2025 grant date and expires on December 11, 2035, subject to his continued employment.

Under which plan were Steven R. King’s Jaguar Health (JAGX) equity awards granted?

The restricted stock units and stock options granted to Steven R. King were issued under Jaguar Health’s 2014 Stock Incentive Plan, as noted in the Form 4 footnotes.

What is Steven R. King’s role at Jaguar Health (JAGX) as referenced in the Form 4?

The Form 4 lists Steven R. King as an officer of Jaguar Health, serving as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary.